Primidone — Mysoline — is the alternative first-line treatment for essential tremor, alongside propranolol. Both agents have comparable efficacy in trials; the choice between them often comes down to patient factors and tolerability. In refractory cases, combining them is more effective than either alone.
- Class
- Anticonvulsants used for tremor
- Mechanism
- Primidone: metabolized to phenobarbital; GABA enhancement and possible direct tremor circuit modulation. Topiramate: multi-mechanism (used for tremor at lower doses than seizures).
- Typical dose
- Primidone 25-750 mg/day (titrate slowly to avoid sedation). Topiramate 25-200 mg/day.
- FDA indications
- Essential tremor (first or second-line)
- Key adverse effects
- Primidone: sedation (significant initially — start very low), fatigue, ataxia. Topiramate: cognitive dulling, paresthesias, weight loss.
- Representative agents
- Primidone (Mysoline), topiramate (Topamax) for tremor
Primidone is the alternative first-line to propranolol for essential tremor. Slow titration is essential — start 25 mg HS, increase weekly. Combination of propranolol + primidone often more effective than either alone for refractory tremor.
The mechanism is anticonvulsant. Primidone itself has GABA enhancing properties; it is also metabolized to phenobarbital and PEMA, both active metabolites that contribute to the antitremor effect. The tremor-specific mechanism isn't fully characterized, but the clinical effect is real.
Primidone and certain anticonvulsants treat essential tremor through neuronal stabilization — an alternative or adjunct to beta-blockers.
Mechanism note: Primidone joins propranolol as first-line for essential tremor; the anticonvulsant alternatives (topiramate, gabapentin) are second-line, and slow titration of primidone manages its early sedation.
The major practical challenge with primidone is the initial sedation. Starting at therapeutic doses produces profound sedation, dizziness, and ataxia — often severe enough that patients refuse to continue. The solution is very slow titration: start 25 milligrams at bedtime, increase weekly, reach 250-750 milligrams over weeks. The patient adapts to the sedation over time. The titration is non-negotiable; rushing it loses the patient.
Once established, primidone is generally well-tolerated long-term. The chronic side effects are typically modest compared to the initial titration challenge.
- Cost
- Primidone generic ~$15-40/month. Topiramate generic ~$10-30/month.
- Generic status
- Both generic for years.
- Formulary typical
- Tier 1 generics.
- Access friction
- None for the medications. Slow titration is the patient adherence concern with primidone.
Prescriber tip: For essential tremor, primidone slow titration is the engagement challenge — counsel patients to commit to the weeks of escalation despite early sedation.
For combination therapy in refractory essential tremor — when propranolol or primidone alone isn't enough — adding the second agent often produces additive benefit. Beyond that, topiramate has some evidence as a third-line option (with its own cognitive side effects). For severely disabling tremor refractory to medications, surgical options exist: deep brain stimulation of the VIM thalamic nucleus, focused ultrasound thalamotomy. These produce dramatic improvement in well-selected patients.
Essential tremor is one of the more common movement disorders. The first-line medications work for most patients. For the rest, the surgical/interventional options are increasingly accessible.